Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Daniel J. Wallace, Kenneth Kalunian, Michelle A. Petri, Vibeke Strand, Frederic A. Houssiau, Marilyn Pike, Brian Kilgallen, Sabine Bongardt, Anna Barry, Lexy Kelley, Caroline Gordon

Research output: Contribution to journal › Article › peer-review

183 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds